TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06186401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E-SYNC T Cells
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E-SYNC T Cells
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E-SYNC T Cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (non-investigational)
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (non-investigational)
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (non-investigational)
Description: Given IV
Study: NCT06223737

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EOS x-ray
Description: After marking the anatomical landmarks where later on skin markers will be placed, radiopaque markers are attached for the radiographic examination with the EOS system. Images are taken from the positions standing and sitting
Study: NCT06186401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (non-investigational)
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (non-investigational)
Description: Given IV
Study: NCT06223737

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: EOS x-ray
Description: After marking the anatomical landmarks where later on skin markers will be placed, radiopaque markers are attached for the radiographic examination with the EOS system. Images are taken from the positions standing and sitting

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: EOS x-ray
Description: After marking the anatomical landmarks where later on skin markers will be placed, radiopaque markers are attached for the radiographic examination with the EOS system. Images are taken from the positions standing and sitting

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motion capture
Description: The used marker set is the IfB marker set (List et al. 2013), consisting of 40 skin markers on the lower extremities, 7 on the pelvis, 24 on the trunk and 6 on the upper extremities. For the later musculoskeletal modelling the IfB marker set is extended with 7 additional markers on the spinal thoracic processes. All markers will be placed by skilled operators.~The test procedure consists of six trials, namely a standing trial in an anatomic upright position and a calibration motion as well as four basic motion tasks to define functional estimated joint axis, respectively centers (each performed twice).~Tasks: standing, maximal flexion-extension, lateral bending, axial rotation, lifting, holding load, walking, step up, sitting and sit-to-stand

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Motion capture
Description: The used marker set is the IfB marker set (List et al. 2013), consisting of 40 skin markers on the lower extremities, 7 on the pelvis, 24 on the trunk and 6 on the upper extremities. For the later musculoskeletal modelling the IfB marker set is extended with 7 additional markers on the spinal thoracic processes. All markers will be placed by skilled operators.~The test procedure consists of six trials, namely a standing trial in an anatomic upright position and a calibration motion as well as four basic motion tasks to define functional estimated joint axis, respectively centers (each performed twice).~Tasks: standing, maximal flexion-extension, lateral bending, axial rotation, lifting, holding load, walking, step up, sitting and sit-to-stand
Study: NCT06186401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (non-investigational)
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Undergo surgical resection of tumor tissue
Study: NCT06496607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Solrikitug Low Dose
Description: Solrikitug Low Dose subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Solrikitug Mid Dose
Description: Solrikitug Mid Dose subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Solrikitug High Dose
Description: Solrikitug High Dose subcutaneous injection

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT05103111

Intervention type: OTHER
Intervention: No intervention
Description: no intervention

Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study: NCT06223737

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Motion capture
Description: The used marker set is the IfB marker set (List et al. 2013), consisting of 40 skin markers on the lower extremities, 7 on the pelvis, 24 on the trunk and 6 on the upper extremities. For the later musculoskeletal modelling the IfB marker set is extended with 7 additional markers on the spinal thoracic processes. All markers will be placed by skilled operators.~The test procedure consists of six trials, namely a standing trial in an anatomic upright position and a calibration motion as well as four basic motion tasks to define functional estimated joint axis, respectively centers (each performed twice).~Tasks: standing, maximal flexion-extension, lateral bending, axial rotation, lifting, holding load, walking, step up, sitting and sit-to-stand
Study: NCT05758493

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 124I-Evuzamitide
Description: Amyloid reactive protein used as imaging agent to detect systemic amyloidosis
Study: NCT05488964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised endurance training with moderate-to-high intensity 3-4 times weekly.
Study: NCT06204666

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dose Hemp Fiber Bar
Description: Low dose hemp fiber bar with other ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bar with other ingredients
Study: NCT06156007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation exercises
Description: Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
Study: NCT05736367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-13C-glucose
Description: Discover new insights into the glucose, TCA cycle, amino acid, and lipid metabolic dependencies of HR+/Her2- breast cancer, via liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo U-13C-glucose-labeled biopsy of tumor and benign adjacent tissue
Study: NCT06473480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abott FreeStyle Libre System 2
Description: The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abott Freestyle Libre Pro
Description: The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
Study: NCT06481735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T cell
Description: Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2 : dose of RP2D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous fludarabine 25\~30 mg/m\^2/day on days -5, -4, and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
Study: NCT04988737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Clinical Decision Support Application
Description: Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
Study: NCT06109805

Intervention type: OTHER
Intervention: Gastric cancer
Description: Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
Study: NCT04970498

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed

Intervention type: DIAGNOSTIC_TEST
Intervention: blood routine test
Description: The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy.
Study: NCT03886181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study: NCT05649332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argogen (silver zeolite powder)
Description: The medical device will be self-administered by each patient twice daily without interruption for the duration of the study (4 weeks) or until complete healing. Application is carried out by spraying at short intervals, lightly pressing the dispenser button and directing the spray onto the area to be treated.
Study: NCT04970498

Intervention type: DIAGNOSTIC_TEST
Intervention: blood routine test
Description: The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood routine test
Description: The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy.
Study: NCT04859140

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychometric ratings (Likert-scale)
Description: Self-report of perceived anxiety and physical sensations (muscle pain, relaxation and warmth)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychometric ratings (Likert-scale)
Description: Self-report of perceived anxiety and physical sensations (muscle pain, relaxation and warmth)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychometric ratings (Likert-scale)
Description: Self-report of perceived anxiety and physical sensations (muscle pain, relaxation and warmth)
Study: NCT04956692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab SC
Description: SC injection
Study: NCT04859140

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Range of motion measures
Description: Sit-and-reach and toe touch tests

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Range of motion measures
Description: Sit-and-reach and toe touch tests

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Range of motion measures
Description: Sit-and-reach and toe touch tests

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental calculation task
Description: Iterated substractions (for 2 minutes)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental calculation task
Description: Iterated substractions (for 2 minutes)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental calculation task
Description: Iterated substractions (for 2 minutes)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resting-state electroencephalography
Description: Alpha and beta oscillation power (4 minutes recordings)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resting-state electroencephalography
Description: Alpha and beta oscillation power (4 minutes recordings)
Study: NCT04956692

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab IV
Description: IV injection
Study: NCT04859140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resting-state electroencephalography
Description: Alpha and beta oscillation power (4 minutes recordings)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resting-state galvanic skin resistance measures
Description: Skin conductance during the resting state period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resting-state galvanic skin resistance measures
Description: Skin conductance during the resting state period
Study: NCT04956692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: IV infusion
Study: NCT05568472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Standard of care hormone therapy and standard visit with clinician

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Standard of care hormone therapy and standard visit with clinician

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo correlative studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocrine Drug Therapy
Description: Undergo endocrine therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine Drug Therapy
Description: Undergo endocrine therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Receive list of websites

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Receive list of websites

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05187988

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular brachial plexus block
Description: group will receive brachial plexus block above clavicle,Injection of anaesthetic will be done in brachial plexus around subclavian artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retroclavicular brachial plexus block
Description: group will receive brachial plexus block inferior to the clavicle,injection of anaesthetic will be done around axillary artery
Study: NCT04893109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab-emtansine
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab SC
Description: Muscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab SC
Description: Muscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intravenous infusion
Study: NCT04859140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resting-state galvanic skin resistance measures
Description: Skin conductance during the resting state period
Study: NCT05568472

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Specific Assessment Tool
Description: Receive a weblink via email or text message and asked 6 brief questions about symptoms
Study: NCT04991935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-93538
Description: CC-93538
Study: NCT06152731

Intervention type: GENETIC
Group type: OTHER
Intervention: tests to determine HRD status
Description: Test Giscar AND test myChoice will be performed.~If one or two tests identifies a HRD status :~a PARP inhibitor treatment may be initiated according to current recommendations
Study: NCT05704725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 938
Description: IVT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: IVT injection
Study: NCT04426812

Intervention type: OTHER
Intervention: No intervention; just data collection
Description: No intervention; just data collection
Study: NCT04858997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI
Description: AI, orally once daily (continuously)
Study: NCT06501105

Intervention type: DEVICE
Intervention: WOUNDCHEK Bacterial Status
Description: Lateral flow point of care test for the qualitative detection of bacterial protease activity in wound fluid.

Intervention type: DEVICE
Intervention: WOUNDCHEK Bacterial Status
Description: Lateral flow point of care test for the qualitative detection of bacterial protease activity in wound fluid.
Study: NCT06274788

Intervention type: DRUG
Intervention: Omegaven® (fish oil triglycerides) Injectable Emulsion
Description: Pediatric patients Pediatric patients with new-onset PNAC~Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion Dose, frequency and duration is a decision of the Investigator
Study: NCT04829448

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement
Description: Protein supplement equivalent to Metagenics Ultrameal
Study: NCT05247255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: QL block with 0.25% ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: QL block with saline
Study: NCT05437263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brepocitinib
Description: Oral Brepocitinib
Study: NCT04956692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study: NCT05355519

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic curriculum and instructor-led course, then placebo
Description: Electronic curriculum and instructor-led course

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, then electronic curriculum and instructor-led course
Description: Electronic curriculum and instructor-led course
Study: NCT05907148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory integration training
Description: Sitting position:~1. Sit in a chair without a backrest while the feet on firm surface. without backrest while the feet on soft surface.~2. Sit on a ball while the feet on firm surface. while feet on soft surface.~3. Sit in a chair without a backrest with the feet on firm surface and perform sit-to-stand motion.~   without a backrest with the feet on soft surface and perform sit-to-stand motion.~4. Sit on a ball with the feet on the firm surface and perform sit-to-stand motion. with the feet on the soft surface and perform sit-to-stand motion.~5. Perform bipedal standing on a firm surface. on a soft surface.~6. Perform a semi-tandem stance on firm surface. on soft surface.~7. Walk forward on firm surface. on soft surface.~8. Walk forward on firm surface, cross obstacle, and continue to walk.~9. Walk forward on the soft surface, cross obstacle, and continue to walk.
Study: NCT04956692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion
Study: NCT05907148

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy
Description: It consist of active joint mobilization, muscle stretching, motor coordination exercises and general balance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy
Description: It consist of active joint mobilization, muscle stretching, motor coordination exercises and general balance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General coordination exercise
Description: In supine lying:~1. Patients are told to place heel of one leg on shin or knee of the other leg,~2. Patient bends one leg and extends the other leg like bicycling motion.~3. Flexing one leg while extending other leg~4. Flexing and extending of one leg while abduction and adduction of other leg.~In sitting:~1. Patient performs marching without backrest or back support,~2. Patient reaches forward and sideways with arms~3. Rotation of trunk with physioball in hand without back support.~4. Patient reaches with legs to marked point in sitting.~In standing:~Patient performs 10 repetitions of~1. Clock Reach~2. Side Leg Raises~3. Leg Swings and~4. Ball catch and throw
Study: NCT05437263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brepocitinib
Description: Oral Brepocitinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo
Study: NCT05112991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab+Lenvatinib
Description: Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.~Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.